EWTX Stock Price, Edgewise Therapeutics, . Quote, Chart

Market Summary

USD17.76+0.32

Delayedas of 15 May 2024, 02:02 pm

1.83%

EWTX Stock Price

View Fullscreen

EWTX RSI Chart

EWTX Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-15.39

Price/Sales (Trailing)

92.78

Price/Free Cashflow

-16.39

EWTX Price/Sales (Trailing)

EWTX Profitability

Return on Equity

-19.79%

Return on Assets

-19.11%

Free Cashflow Yield

-6.1%

EWTX Fundamentals

EWTX Revenue

Revenue (TTM)

17.6M

Rev. Growth (Yr)

117.31%

Rev. Growth (Qtr)

67.46%

EWTX Earnings

Earnings (TTM)

-105.8M

Earnings Growth (Yr)

-24.9%

Earnings Growth (Qtr)

5.37%

Breaking Down EWTX Revenue

52 Week Range

5.4918.14

(Low)(High)

Last 7 days

-17.9%

Last 30 days

6.5%

Last 90 days

-2.8%

Trailing 12 Months

93.2%

How does EWTX drawdown profile look like?

EWTX Financial Health

Current Ratio

37.08

Debt/Equity

1e-4

Debt/Cashflow

-1.7K

EWTX Investor Care

Shares Dilution (1Y)

47.60%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	17.6M	0	0	0
2023	6.7M	10.2M	13.1M	14.2M
2022	526.0K	843.0K	1.5M	4.0M
2021	48.0K	152.0K	278.0K	402.0K
2020	0	0	0	69.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Edgewise Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	derakhshan behrad	sold	-32,487	18.91	-1,718	chief business officer
May 02, 2024	koch kevin	sold	-59,604	18.91	-3,152	president and ceo
May 02, 2024	russell alan j	sold	-29,802	18.91	-1,576	chief scientific officer
May 02, 2024	carruthers r michael	sold	-40,788	18.91	-2,157	chief financial officer
May 02, 2024	moore john r	sold	-36,988	18.91	-1,956	general counsel
May 02, 2024	donovan joanne m.	sold	-69,626	18.91	-3,682	cmo
May 01, 2024	moore john r	acquired	-	-	5,208	general counsel
May 01, 2024	koch kevin	acquired	-	-	10,417	president and ceo
May 01, 2024	carruthers r michael	acquired	-	-	5,208	chief financial officer
May 01, 2024	derakhshan behrad	acquired	-	-	5,208	chief business officer

Which funds bought or sold EWTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	HRT FINANCIAL LP	sold off	-100	-424,000	-	-%
May 13, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	33.62	285,683	518,344	-%
May 13, 2024	Ameritas Investment Partners, Inc.	added	37.26	59,059	104,898	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	reduced	-29.83	120,000	828,000	-%
May 13, 2024	NATIXIS	sold off	-100	-82,650	-	-%
May 13, 2024	FOX RUN MANAGEMENT, L.L.C.	new	-	197,247	197,247	0.04%
May 13, 2024	UBS Group AG	new	-	1,351,910	1,351,910	-%
May 13, 2024	Lighthouse Investment Partners, LLC	new	-	1,110,470	1,110,470	0.05%
May 13, 2024	STRS OHIO	new	-	229,000	229,000	-%
May 13, 2024	XTX Topco Ltd	reduced	-18.05	68,710	256,254	0.04%

Are Funds Buying or Selling EWTX?

Are funds buying EWTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EWTX

No. of Funds

Unveiling Edgewise Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	4.00%	2,537,176	SC 13G/A
Feb 14, 2024	viking global investors lp	9.7%	6,159,146	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	blackrock inc.	4.1%	3,505,199	SC 13G/A
Feb 02, 2024	blackrock inc.	5.2%	3,307,110	SC 13G
Feb 01, 2024	flynn james e	0.64%	545,455	SC 13G/A
Jan 29, 2024	ra capital management, l.p.	9.6%	8,909,091	SC 13G
Jan 25, 2024	novo holdings a/s	7.4%	6,344,430	SC 13D/A
Jan 25, 2024	orbimed advisors llc	17.3%	14,756,096	SC 13D/A
Jun 28, 2023	novo holdings a/s	9.6%	6,071,703	SC 13D/A

Recent SEC filings of Edgewise Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 10, 2024	8-K	Current Report
May 10, 2024	S-3ASR	S-3ASR
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 09, 2024	S-8	Employee Benefits Plan
May 07, 2024	3	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	8-K	Current Report
May 07, 2024	DEFA14A	DEFA14A
May 03, 2024	4	Insider Trading

Peers (Alternatives to Edgewise Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	22.08%	-1.47%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.34%	-28.23%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-13.63%	-16.32%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	5.96%	-13.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	8.09%	95.42%	-9.91	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-20.37%	-53.19%	-11.98	9.54	394.93%	39.61%
AXSM	3.7B	251.0M	11.93%	-0.48%	-12.39	14.63	73.58%	-86.73%
ARWR	2.8B	240.7M	-7.33%	-42.62%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.36%	-32.87%	-1.4K	3.02	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	8.34%	25.49%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	214.95%	66.21%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	4.53%	306.67%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.99%	24.13%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-6.93%	99.64%	-0.7	7.61	-13.45%	69.54%

Edgewise Therapeutics, Inc. News

Latest updates

Edgewise Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	67.5%	6,228	3,719	3,739	3,870	2,866	2,664	764	424	166	126	127	107	42.00	2.00	1.00	3.00	63.00
Operating Expenses	2.6%	34,753	33,862	29,452	25,339	25,704	22,079	18,262	16,491	14,826	12,822	13,076	10,460	6,857	6,344	3,643	3,957	3,248
S&GA Expenses	-100.0%	-	6,178	5,666	5,780	5,828	5,467	4,368	4,089	3,702	3,734	3,196	2,599	1,497	1,205	405	318	281
R&D Expenses	0.0%	27,694	27,684	23,786	19,559	19,876	16,612	13,894	12,402	11,124	9,088	9,880	7,861	5,360	5,139	3,238	3,639	2,967
Net Income	5.4%	-28,525	-30,143	-25,713	-21,469	-22,838	-19,415	-17,498	-16,067	-14,660	-12,696	-12,949	-10,353	-6,815	-6,342	-3,642	-3,954	-3,185
Net Income Margin	14.6%	-6.03*	-7.06*	-6.81*	-7.99*	-11.29*	-16.83*	-41.16*	-66.87*	-96.31*	-106.50*	-131.15*	-178.63*	-	-	-	-	-
Free Cashflow	-7.1%	-28,895	-26,991	-22,515	-20,993	-27,194	-15,148	-13,293	-16,799	-12,941	-9,498	-8,713	-9,845	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	62.9%	554	340	311	331	346	367	377	257	273	285	294	303	311	131
Current Assets	65.6%	541	327	298	317	333	357	370	253	269	284	293	303	311	130
Cash Equivalents	-64.8%	30.00	86.00	33.00	32.00	48.00	22.00	110	18.00	34.00	16.00	11.00	50.00	221	105
Net PPE	-2.5%	10.00	10.00	11.00	11.00	10.00	9.00	5.00	2.00	1.00	1.00	1.00	1.00	0.00	1.00
Liabilities	-11.0%	19.00	21.00	21.00	19.00	18.00	20.00	16.00	11.00	12.00	11.00	9.00	-	-	4.00
Current Liabilities	-12.9%	15.00	17.00	16.00	14.00	13.00	17.00	13.00	9.00	10.00	11.00	9.00	7.00	5.00	4.00
Short Term Borrowings	-	-	-	-	-	-	-	0.00	-	-	-	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	0.00	-	-	-	-	-	-	-
Shareholder's Equity	67.8%	535	319	290	311	329	347	361	246	260	274	285	297	306	-
Retained Earnings	-11.7%	-273	-244	-214	-188	-167	-144	-125	-107	-91.62	-76.96	-64.30	-51.30	-41.00	-34.15
Additional Paid-In Capital	43.6%	809	563	505	501	497	493	489	356	354	352	350	348	347	1.00
Accumulated Depreciation	18.1%	3.00	3.00	-	-	-	-	-	1.00	1.00	1.00	1.00	1.00	1.00	0.00
Shares Outstanding	32.4%	93.00	70.00	63.00	63.00	63.00	63.00	52.00	50.00	50.00	50.00	49.00	26.00	-	-
Float	-	-	-	-	386	-	-	-	248	-	-	-	653	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-6.6%	-28,598	-26,830	-22,058	-20,234	-22,826	-11,855	-11,963	-16,245	-12,572	-9,419	-8,262	-9,769	-6,057	-4,638	-3,272	-3,985	-2,739
Share Based Compensation	-5.5%	4,871	5,153	4,559	4,011	3,837	3,736	3,173	2,037	1,978	1,873	1,548	687	296	190	70.00	49.00	45.00
Cashflow From Investing	-1094.4%	-268,308	26,983	23,419	3,442	49,042	-75,596	-26,321	-46.00	31,386	14,121	-31,608	-159,967	-64,773	-24,178	-6.00	-188	-9.00
Cashflow From Financing	355.0%	241,073	52,987	-211	369	21.00	-303	129,690	179	73.00	293	37.00	-896	186,950	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EWTX Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 27,694	$ 19,876
General and administrative	7,059	5,828
Total operating expenses	34,753	25,704
Loss from operations	(34,753)	(25,704)
Other income
Interest income	6,228	2,866
Total other income	6,228	2,866
Net loss	(28,525)	(22,838)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities	(960)	1,104
Total comprehensive loss	$ (29,485)	$ (21,734)
Net loss per share, basic (in dollars per share)	$ (0.33)	$ (0.36)
Net loss per share, diluted (in dollars per share)	$ (0.33)	$ (0.36)
Weighted-average shares outstanding, basic	87,567,307	63,265,800
Weighted-average shares outstanding, diluted	87,567,307	63,265,800

EWTX Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 30,264	$ 86,097
Marketable securities, available for sale	502,495	232,296
Prepaid expenses and other assets	8,668	8,604
Total current assets	541,427	326,997
Property and equipment, net	10,184	10,443
Operating lease right-of-use asset	2,195	2,247
Other non-current assets		348
Total assets	553,806	340,035
Current liabilities
Accounts payable	4,723	4,025
Accrued compensation	2,924	5,695
Accrued other expenses	5,969	6,071
Operating lease liability, current portion	984	980
Total current liabilities	14,600	16,771
Operating lease liability, net of current portion	4,265	4,434
Total liabilities	18,865	21,205
Commitments and contingencies (see note 5)
Stockholders' equity:
Preferred stock, $.0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023
Common stock, $.0001 par value per share; 1,000,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 93,284,528 shares and 70,453,342 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	9	7
Additional paid-in capital	809,081	563,487
Accumulated other comprehensive income (loss)	(861)	99
Accumulated deficit	(273,288)	(244,763)
Total stockholders' equity	534,941	318,830
Total liabilities and stockholders' equity	$ 553,806	$ 340,035

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.

CEO	Dr. Kevin Koch Ph.D.
WEBSITE	edgewisetx.com
INDUSTRY	Biotechnology
EMPLOYEES	74

Edgewise Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Edgewise Therapeutics, Inc.? What does EWTX stand for in stocks?

EWTX is the stock ticker symbol of Edgewise Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Edgewise Therapeutics, Inc. (EWTX)?

As of Tue May 14 2024, market cap of Edgewise Therapeutics, Inc. is 1.63 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EWTX stock?

You can check EWTX's fair value in chart for subscribers.

What is the fair value of EWTX stock?

You can check EWTX's fair value in chart for subscribers. The fair value of Edgewise Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Edgewise Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EWTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Edgewise Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether EWTX is over valued or under valued. Whether Edgewise Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Edgewise Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EWTX.

What is Edgewise Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 14 2024, EWTX's PE ratio (Price to Earnings) is -15.39 and Price to Sales (PS) ratio is 92.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EWTX PE ratio will change depending on the future growth rate expectations of investors.